To explore the prognostic value of the distance between the two lesions that were farthest apart (Dmax) on baseline 18F-FDG PET/CT in peripheral T lymphoma (PTCL) and establish a new prognostic model for predicting the survival outcomes of patients with PTCL.
In this study, a retrospective analysis of 95 patients with PTCL who underwent baseline 18F-FDG PET/CT was performed to assess the predictive value of Dmax. The total metabolic tumour volume (TMTV), total lesion glycolysis (TLG), standardized uptake value (SUV), and Dmax were calculated with LIFEx software. Progression-free survival (PFS) and overall survival (OS) were used as endpoints. The prognostic model was developed based on the results of the multivariate analysis. The time-dependent area under the ROC curve (tdAUC), calibration curves, Harrell C-index, and decision curve analysis (DCA) were used to assess the model.
Patients were followed up for a median of 17.0 months. Multivariate analysis showed that bone marrow biopsy (BMB) and Dmax were independent predictors of PFS (HR: 1.889, P = 0.039; HR: 1.965, P = 0.047) and OS (HR: 1.923, P = 0.031; HR: 1.982, P = 0.034). The model consisting of Dmax, TMTV, and BMB had substantial prognostic value for survival outcomes of PTCL and could successfully identify four groups of patients with significantly different prognoses (χ2 = 13.731, P = 0.003 for PFS; χ2 = 11.841, P = 0.008 for OS). The tdAUC, C-index, calibration curves, and DCA supported that the model was superior to the prognostic index for T-cell lymphoma (PIT) and International Prognostic Index (IPI) scores.
BMB and Dmax were independent predictors of PTCL in our study. Moreover, a prognostic model based on the Dmax, TMTV, and BMB could be useful for predicting the survival outcomes of patients with PTCL.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Agostinelli C, Piccaluga PP, Went P, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol. 2008;61(11):1160–7. https://doi.org/10.1136/jcp.2008.055335.
Vose J, Armitage J, Weisenburger D. International T-Cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. https://doi.org/10.1200/JCO.2008.16.4558.
Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–7. https://doi.org/10.1182/blood-2014-04-573089.
d’Amore F, Gaulard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108–15. https://doi.org/10.1093/annonc/mdv201.
Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123(17):2636–44. https://doi.org/10.1182/blood-2013-12-516245.
Gutiérrez-García G, García-Herrera A, Cardesa T, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22(2):397–404. https://doi.org/10.1093/annonc/mdq359.
Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Aggressives). Ann Oncol. 1990;1(1):45–50. https://doi.org/10.1093/oxfordjournals.annonc.a057673.
Foss F. Hematology: relapsed and refractory PTCL–into the therapeutic abyss. Nat Rev Clin Oncol. 2011;8(6):321–2. https://doi.org/10.1038/nrclinonc.2011.51.
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94. https://doi.org/10.1056/NEJM199309303291402.
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42. https://doi.org/10.1182/blood-2013-09-524108.
Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9. https://doi.org/10.1182/blood-2003-09-3080.
Nakaya A, Fujita S, Satake A, et al. Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma. Leuk Res Rep. 2016;6:24–6. https://doi.org/10.1016/j.lrr.2016.06.003.
Adams HJ, Kwee TC. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;106:55–63. https://doi.org/10.1016/j.critrevonc.2016.07.003.
Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010;28(11):1896–903. https://doi.org/10.1200/JCO.2009.26.5942.
Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Trans. 2009;15(2):242–8. https://doi.org/10.1016/j.bbmt.2008.11.026.
Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood. 2007;109(3):905–9. https://doi.org/10.1182/blood-2006-04-019901.
Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin’s lymphoma. Ann Oncol. 2010;21(1):126–32. https://doi.org/10.1093/annonc/mdp271.
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–58. https://doi.org/10.1200/JCO.2013.53.5229. (published correction appears in J Clin Oncol 2016 Jul 20;34(21):2562).
Zhang Y, Wang G, Zhao X, et al. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). BMC Med Imaging. 2021;21(1):145. https://doi.org/10.1186/s12880-021-00674-5.
Cottereau AS, Becker S, Broussais F, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27(4):719–24. https://doi.org/10.1093/annonc/mdw011.
Cottereau AS, Meignan M, Nioche C, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†. Ann Oncol. 2021;32(3):404–11. https://doi.org/10.1016/j.annonc.2020.11.019.
Cottereau AS, Nioche C, Dirand AS, et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med. 2020;61(1):40–5. https://doi.org/10.2967/jnumed.119.229450.
Eertink JJ, van de Brug T, Wiegers SE, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49(3):932–42. https://doi.org/10.1007/s00259-021-05480-3.
Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Nizzoli ME, Ciavarella S, Vegliante MC, Nioche C, Meignan M, Merli F, Versari A, Ciarrocchi A, Buvat I, Luminari S. Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin lymphoma patients: a radio-genomic study. Hematol Oncol. 2022;40(4):645–57. https://doi.org/10.1002/hon.3025.
Zhou Y, Zhang X, Qin H, et al. Prognostic values of baseline 18F-FDG PET/CT in patients with peripheral T-cell lymphoma. Biomed Res Int. 2020. https://doi.org/10.1155/2020/9746716.
Jiang C, Teng Y, Chen J, et al. Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL). EJNMMI Res. 2020;10(1):110. https://doi.org/10.1186/s13550-020-00698-y.
Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200. https://doi.org/10.1007/s00259-009-1297-4.
Feeney J, Horwitz S, Gönen M, Schöder H. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol. 2010;195(2):333–40. https://doi.org/10.2214/AJR.09.3665.
Chang CC, Cho SF, Chuang YW, et al. Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget. 2017;8(59):99587–600. https://doi.org/10.18632/oncotarget.20447.
Liang JH, Zhang YP, Xia J, et al. Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma. Cancer Res Treat. 2019;51(4):1479–87. https://doi.org/10.4143/crt.2018.649.
Yi S, An G, Qi J, et al. The significance of bone marrow involvement in aggressive lymphomas: a retrospective comparison of clinical outcomes between peripheral T cell lymphoma and diffuse large B cell lymphoma in China. Acta Haematol. 2010;124(4):239–44. https://doi.org/10.1159/000321544.
Koh Y, Lee JM, Woo GU, et al. FDG PET for evaluation of bone marrow status in T-cell lymphoma. Clin Nucl Med. 2019;44(1):4–10. https://doi.org/10.1097/RLU.0000000000002320.
Abe Y, Kitadate A, Usui Y, et al. Diagnostic and prognostic value of using 18F-FDG PET/CT for the evaluation of bone marrow involvement in peripheral T-cell lymphoma. Clin Nucl Med. 2019;44(5):e336–41. https://doi.org/10.1097/RLU.0000000000002516.
Hwang JP, Lim I, Byun BH, Kim BI, Choi CW, Lim SM. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma. Nucl Med Commun. 2016;37(12):1267–72. https://doi.org/10.1097/MNM.0000000000000579.
Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: a multicenter, retrospective analysis. Am J Otolaryngol. 2018;39(1):1–5. https://doi.org/10.1016/j.amjoto.2017.10.009.
Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol. 2010;28(2):57–61. https://doi.org/10.1002/hon.905.
Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2013;119(6):1195–202. https://doi.org/10.1002/cncr.27855.
Yang J, Zhu S, Pang F, et al. Functional parameters of 18F-FDG PET/CT in patients with primary testicular diffuse large B-cell lymphoma. Contrast Media Mol Imaging. 2018. https://doi.org/10.1155/2018/8659826.
Nols N, Mounier N, Bouazza S, et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(4):773–80. https://doi.org/10.3109/10428194.2013.831848.
Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(9):1735–43. https://doi.org/10.1007/s00259-014-2783-x.
Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–19. https://doi.org/10.1007/s00259-016-3315-7.
Cottereau AS, Lanic H, Mareschal S, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large b-cell lymphoma. Clin Cancer Res. 2016;22(15):3801–9. https://doi.org/10.1158/1078-0432.CCR-15-2825.
The research did not receive specific funding.
Conflict of interest
The authors declare that they have no competing interests.
This study was conducted in accordance with the ethical standards set out in the 1964 Declaration of Helsinki and all subsequent revisions.
Consent to participate
Approval was obtained from the institution review boards, and all of the subjects signed a written consent form.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Xie, Y., Teng, Y., Jiang, C. et al. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL). Jpn J Radiol 41, 777–786 (2023). https://doi.org/10.1007/s11604-023-01398-y